Is it really happening? Astatine-211 is a promising new radionuclide being further developed and researched for the treatment of cancer. It is a short half-life alpha-emitter that's attracting more interest from the nuclear medicine community as investors take notice of its potential and production capacity improves. So where will 211At be by 2030? And is this a radionuclide that could show up in a clinical setting in the near future? Join host Ken Herrmann, MD with guests Brenda Sandmaier, MD, Tadashi Watabe, MD, and Ferid Haddad PhD, as they discuss the future of this isotope.
This episode is sponsored by IBA Radiopharma Solutions (https://www.iba-radiopharmasolutions.com/) and Accelerate.eu (https://ihi-accelerate.eu/)
Popular Podcasts
Spooky Podcasts from iHeartRadio
Whether you’re a scaredy-cat or a brave bat, this collection of episodes from iHeartPodcasts will put you in the Halloween spirit. Binge stories, frights, and more that may keep you up at night!
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.